DOLOMITE NEAT ID Network Study: A prospective, multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women (208759)

Study identification

• EU PAS number:
  EUPAS24237
• Study ID:
  41940
• Official title and acronym:
  DOLOMITE NEAT ID Network Study: A prospective, multi-site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women (208759)
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  France

  Italy

  Poland

  Portugal

  Spain

  Ukraine

  United Kingdom
• Study status:
  Ongoing

Research institutions and networks

Institutions

ViiV Healthcare

Study timelines

Date when funding contract was signed

Planned: 20/11/2017

Actual: 20/11/2017

Study start date

Planned: 18/11/2019

Actual: 18/11/2019

Date of final study report

Planned: 31/12/2025

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Viiv Healthcare

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)